You are here

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Elite Research Institute
Miami, Florida, 33169 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes Mellitus, NIDDM
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with type 2 diabetes mellitus who are taking metformin only.

- Treatment should be stable, where this is defined as no change in the treatment,
including dose, over the past 2 months. Regimens may include once daily and twice
daily dosing only.

- Male and/or female patients (females will be women of non childbearing potential)

- Body Mass Index (BMI) of 18.5 to 45.0 kg/m2; and a total body weight >50 kg (110 lbs).

- HbA1c between 7.0% and 10.0%.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at time of dosing). Patients who have chronic conditions other than
T2DM (for example, hypercholesterolemia or hypertension) but are controlled by either
diet or stable (for the last 2 months) doses of medications may be included as well
(for example, a subject with hypercholesterolemia on appropriate treatment is
eligible).

- Evidence or history of diabetic complications with significant end organ damage, eg,
proliferative retinopathy and/or macular edema, creatinine clearance less than 60
mL/min

- Any condition possibly affecting drug absorption (eg, gastrectomy)

- History of stroke or transient ischemic attack or myocardial infarction within the
past 6 months

- History of coronary artery bypass graft or stent implantation.

- Clinically significant peripheral vascular disease (eg, manifested by claudication).

- Any history or clinical evidence of congestive heart failure, NYHA Classes II to IV.

- One or more self reported significant/severe/requiring treatment episodes of
hypoglycemia within the last 3 months, or two or more self reported
significant/severe/requiring treatment episodes of hypoglycaemia within the last 6
months.

- Current history of angina/unstable angina.

- Milk or soy allergy

NCT01272804
Pfizer
Completed
Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Type 2 Diabetes Mellitus, NIDDM
NCT01272804
All Genders
18+
Years
Multiple Sites
Type 2 Diabetes Mellitus
NCT01522807
All Genders
21+
Years
Singapore,
Diabetes Mellitus, Type 2 Diabetes Mellitus, Glucose Metabolism Disorders
NCT01129258
All Genders
18+
Years
Multiple Sites
Coronary Arteriosclerosis, Type 2 Diabetes Mellitus, Cerebrovascular Accident, Dyslipidemia, Peripheral Vascular Disease
NCT00442845
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now